Evidence map›Paper›PMID 35329942›Full record

ArticleJournal of clinical medicine2022

Clinical Outcomes after Surgical Resection Combined with Brachytherapy for Uveal Melanomas.

Isabel Relimpio-López, Antonio Manuel Garrido-Hermosilla, Francisco Espejo, María Gessa-Sorroche, Lourdes Coca, Belen Domínguez, María Jesús Díaz-Granda, Beatriz Ponte, María José Cano, Enrique Rodríguez de la Rúa and 7 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Isabel Relimpio-LópezDepartment of Ophthalmology, Virgen Macarena University Hospital, 41009 Seville, Spain.ORCID 0000-0002-2872-2940
Antonio Manuel Garrido-HermosillaDepartment of Ophthalmology, Virgen Macarena University Hospital, 41009 Seville, Spain.ORCID 0000-0002-7664-676X
Francisco EspejoDepartment of Ophthalmology, Virgen Macarena University Hospital, 41009 Seville, Spain.
María Gessa-SorrocheDepartment of Ophthalmology, Virgen Macarena University Hospital, 41009 Seville, Spain.ORCID 0000-0001-5417-1495
Lourdes CocaDepartment of Ophthalmology, Virgen Macarena University Hospital, 41009 Seville, Spain.
Belen DomínguezDepartment of Ophthalmology, Virgen Macarena University Hospital, 41009 Seville, Spain.ORCID 0000-0003-0591-0401
María Jesús Díaz-GrandaDepartment of Ophthalmology, Virgen Macarena University Hospital, 41009 Seville, Spain.
Beatriz PonteDepartment of Ophthalmology, Virgen Macarena University Hospital, 41009 Seville, Spain.
María José CanoDepartment of Ophthalmology, Virgen Macarena University Hospital, 41009 Seville, Spain.
Enrique Rodríguez de la RúaDepartment of Ophthalmology, Virgen Macarena University Hospital, 41009 Seville, Spain.
Francisco Carrasco-PeñaDepartment of Radiation Oncology, Virgen Macarena University Hospital, 41009 Seville, Spain.
Carlos MíguezDepartment of Radiation Oncology, Virgen Macarena University Hospital, 41009 Seville, Spain.
Jonathan SaavedraDepartment of Radiation Oncology, Virgen Macarena University Hospital, 41009 Seville, Spain.
Antonio OntanillaDepartment of Anesthesiology, Virgen Macarena University Hospital, 41009 Seville, Spain.
Carlos Caparrós-EscuderoDepartment of Radiology, Virgen Macarena University Hospital, 41009 Seville, Spain.
Juan José RíosDepartment of Pathology, Virgen Macarena University Hospital, 41009 Seville, Spain.
José Antonio TerrónDepartment of Radio Physics, Virgen Macarena University Hospital, 41009 Seville, Spain.ORCID 0000-0001-5123-9597
Hospital Universitario Virgen Macarena · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, brachytherapy is the most commonly used therapeutic approach for uveal melanomas. Surgical resection by means of endoresection or exoresection is an alternative approach. The present report recounts our experience over 15 years in the treatment of uveal melanoma using a combined approach of resection surgery with brachytherapy. This is a single-center observational retrospective cohort study in which we describe clinical outcomes, complications and survival in 35 cases of melanoma of the iris or the ciliary body after a combination of surgery and brachytherapy or brachytherapy alone. Local treatment of the tumor was successful in all cases with surgery and brachytherapy. The most frequent complications were scleromalacia, bullous keratopathy, retinal toxicity, cataracts, hypotonia, and photophobia. There were three cases of recurrence, all of which were found in the group of patients who had received brachytherapy alone, and in one case we had to perform a secondary enucleation due to tumor growth after brachytherapy. At present, only one patient has died during follow-up due to liver metastases six years after the start of treatment. In carefully selected patients, this approach can be effective and safe, as long as a close follow-up is carried out after surgery.

Indexed as

brachytherapyexoresectionsurgeryuveal melanoma

Identifiers

PMID35329942
PMCPMC8956023
OpenAlexW4220658256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.